Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för telatinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2022-09-28

Identification of stable housekeeping genes for induced pluripotent stem cells and -derived endothelial cells for drug testing.

Ong SLM, Baelde HJ, van IJzendoorn DGP, Bovée JVMG, Szuhai K.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-022-20435-w

Bibliografisk träff 2018-03-06

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-17-3512

Bibliografisk träff 2014-09-29

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.

Wang YJ, Zhang YK, Kathawala RJ, Chen ZS.

Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers6041925

Bibliografisk träff 2014-02-22

Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS.

Biochem Pharmacol · research-article; journal article · DOI 10.1016/j.bcp.2014.02.012

Bibliografisk träff 2011-07-29

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, Büchert M, Krätzschmer J, Delesen H, Rajagopalan P, Christensen O.

Vasc Cell · research-article; journal article · DOI 10.1186/2045-824x-3-16

Bibliografisk träff 2011-03-04

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE.

Ann Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdq767

Bibliografisk träff 2010-03-16

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE.

Clin Cancer Res · multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-09-2436

Bibliografisk träff 2009-11-19

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

Steeghs N, Gelderblom H, Wessels J, Eskens FA, de Bont N, Nortier JW, Guchelaar HJ.

Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-009-9347-0

Bibliografisk träff 2009-07-27

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.

J Clin Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1200/jco.2008.18.8193

Bibliografisk träff 2008-11-01

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K.

Br J Cancer · other; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/sj.bjc.6604724

Bibliografisk träff 2008-06-01

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E.

Clin Cancer Res · clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-07-5050